2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|July 16, 2019
Suheung Opens Capsule Factory
Author(s)Pharmaceutical Technology Editors
Suheung’s new facility in Vietnam is dedicated to vegetarian capsule manufacturing.
Advertisement
Suheung Co., Ltd. has opened an EMBO CAPS VG-ALPHA capsule facility located in the Long Thanh Industrial Zone (Dong Nai Province), Vietnam, the company announced on June 15, 2019. The vegetarian capsule manufacturing facility will supply capsules globally under the Embocaps by Suheung brand and increase the capacity of the popular EMBO CAPS VG-ALPHA vegetarian capsule, the company reported in a press statement.
“This facility is an investment in the future of the industry. Availability should never hinder growth. Our new Alpha plant demonstrates our commitment to support our customer’s success for today and tomorrow,” JooHwan Yang, company chairman and chief executive officer explained in the press statement.
The Embocaps vegetarian capsule product line includes the EMBO CAPS VG and EMBO CAPS VG-ALPHA, non-animal alternatives to gelatin capsules; the EMBO CAPS AP, a non-animal delayed release capsule; and the EMBO CAPS VP, a pullulan-based capsule.
“The new EMBO CAPS VG Alpha facility utilizes the most advanced technology available. The plant was built around the process, not a process built into a plant; this difference maximizes both the production efficiency and product quality. I am very proud of the finished result.” stated Sung Gul Yoon, company vice-chairman and chief architect of the proprietary EMBO CAPS VG-ALPHA production process in the press statement.
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement